Table 1 Clinical trials of gp96 tumor vaccine in glioma
From: Immunotherapy with heat shock protein 96 to treat gliomas
NCT Number | Start Date | Location | Sponsor/Collaborators | Enrollment | Disease | Interventions | Status |
|---|---|---|---|---|---|---|---|
NCT00293423 | 2005/10/1 | US | UCSF Department of Neurosurgery San Francisco, California, United States, | 41 | Adult glioblastoma;Recurrent adult brain tumor | HSPPC-96a with Temozolomide and radiotherapy | Completed |
NCT00905060 | 2009/6/1 | US | University of California, San Francisco | 70 | Newly diagnosed GBM | HSPPC-96 with Temozolomide and radiotherapy | Completed |
NCT01814813 | 2013/5/1 | US | Alliance for Clinical Trials in Oncology | 90 | Recurrent Glioblastoma; | HSPPC-96 with bevacizumab | Active, not recruiting |
T02122822 | 2013/7/1 | China | Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China | 20 | Supratentoria Glioma | HSPPC-96 with Temozolomide and radiotherapy | Completed |
NCT02722512 | 2016/7/1 | US | Ann & Robert H Lurie Children's Hospital of Chicago | Northwestern University | 20 | GBM; Astrocytoma;Anaplastic Ependymoma | HSPPC-96 with Radiation | Recruiting |
NCT03018288 | 2017/9/21 | US | National Cancer Institute (NCI) | National Institutes of Health Clinical Center (CC) | 108 | Glioblastoma | HSPPC-96 with radiation, temozolomide and Pembrolizumab-96 | Recruiting |
NCT03650257 | 2018/8/20 | China | Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China | 150 | Glioma of Brain | HSPPC-96 with Temozolomide and radiotherapy | Recruiting |